Pediatrics. Consilium MedicumPediatrics. Consilium Medicum2658-66302658-6622Consilium Medicum6250110.26442/26586630.2020.4.200579Conference Report, Theses of ReportOn the issue of symptomatic treatment of respiratory infections in children during the COVID-19 seasonZakharovaIrina N.<p>Doctor of Medical Sciences, Professor, Head of the Department. acad. G.N. Speransky, Honored Doctor of the Russian Federation</p>zakharova-rmapo@yandex.ruRussian Medical Academy of Continuous Professional Education02122020425300203202102032021Copyright © 2020, Consilium Medicum2020<p>The current epidemic season is characterized by a high incidence of acute respiratory viral infections and a new coronavirus infection among children. A significant part of children suffer from respiratory infections in mild and moderately severe forms, and only need symptomatic therapy, which includes antipyretic therapy. Both with a banal respiratory infection, and with COVID-19, ibuprofen and paracetamol can be used.</p>acute respiratory viral infectionsCOVID-19feveribuprofenparacetamolchildrenострые респираторные вирусные инфекцииCOVID-19лихорадкаибупрофенпарацетамолдети[Усенко Д.В., Горелова Е.А., Каннер Е.В. Рациональный подход к терапии ОРВИ и гриппа в клинической практике врача-педиатра. РМЖ. 2015; 3: 174. [Usenko D.V., Gorelova E.A., Kanner E.V. Ratsional’nyi podkhod k terapii ORVI i grippa v klinicheskoi praktike vracha-pediatra. RMZh. 2015; 3: 174 (in Russian).]][CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children – United States, February 12 – April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (14): 422–6.][Wang W, Xu Y, Gao R et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens JAMA 2020; 323 (18): 1843–4.][Методические рекомендации «Особенности клинических проявлений и лечения заболевания, вызванного новой коронавирусной инфекцией (COVID-19) у детей». Версия 2 (утв. Минздравом России). [Metodicheskie rekomendatsii “Osobennosti klinicheskikh proiavlenii i lecheniia zabolevaniia, vyzvannogo novoi koronavirusnoi infektsiei (COVID-19) u detei”. Versiia 2 (utv. Minzdravom Rossii) (in Russian).]][Available from: https://www.nice.org.uk/guidance/ng143/chapter/Recommendations#antipyretic-interventions][Sullivan JE, Farrar HC. Section on Clinical Pharmacology and Therapeutics; Committee on Drugs. Fever and antipyretic use in children. Pediatrics 2011; 127 (3): 580–7.][Hay AD, Costelloe C, Redmond NM et al. Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial. BMJ 2008; 337: a1302.][Kelley MT, Walson PD, Edge JH et al. Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. Clin Pharmacol Therapeutics 1992; 52 (2): 181–9.][Kanabar D. A practical approach to the treatment of low-risk childhood fever. Drugs R D 2014; 14 (2): 45–55. DOI: 10.1007/s40268-014-0052-x][Hämäläinen ML. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997; 48: 103–7.][Poddighe D, Brambilla I, Licari A, Marseglia G. Ibuprofen for Pain Control in Children: New Value for an Old Molecule. Pediatr Emerg Care 2019; 35 (6): 448–53.][Pierce CA, Voss B. Efficacy and Safety of Ibuprofen and Acetaminophen in Children and Adults: A Meta-Analysis and Qualitative Review. Ann Pharmacother 2010; 44 (3): 489–506.][Southey ER, Soares-Wieser K, Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin 2009; 25 (9): 2207–22.][Баранов А.А., Таточенко В.К., Бакрадзе М.Д. Лихорадящий ребенок. Протоколы диагностики и лечения. М., 2015. [Baranov A.A., Tatochenko V.K., Bakradze M.D. Likhoradiashchii rebenok. Protokoly diagnostiki i lecheniia. Moscow, 2015 (in Russ.).]][Kanabar D et al. A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthma-related symptoms. Clin Ther 2007; 29: 2716–23.][Kanabar D. A clinical and safety review of paracetamol and ibuprofen in children. Inflammopharmacology 2017; 25 (1): 1–9. DOI: 10.1007/s10787-016-0302-3][Lesko SM, Mitchell AA. An Assessment of the Safety of Pediatric Ibuprofen: A Practitioner-Based Randomized Clinical Trial. JAMA. 1995; 273 (12): 929–33.][Barbagallo M, Sacerdote P. Ibuprofen in the treatment of children’s inflammatory pain: a clinical and pharmacological overview. Minerva Pediatr 2019; 71 (1): 82–99. DOI: 10.23736/S0026-4946.18.05453-1][Нурофен® для детей, суспензия для приема внутрь (апельсиновая, клубничная). Фармакотерапевтическая группа: НПВП. Рег. уд. П №014745/01. [Nurofen® dlia detei, suspenziia dlia priema vnutr’ (apel’sinovaia, klubnichnaia). Farmakoterapevticheskaia gruppa: NPVP. Reg. ud. P no. 014745/01 (in Russian).]][Ушкалова Е. Проблемы безопасности анальгетиков у детей. Врач. 2012; 8: 32–6. [Ushkalova E. Problemy bezopasnosti anal’getikov u detei. Vrach. 2012; 8: 32–6 (in Russian).]][Rainsford KD. Pharmacology and toxicology of ibuprofen. In: Rainsford KD. Ibuprofen. A critical bibliographic review. London: Taylor & Francis, 1999; p. 145–27.][Argentieri J, Morrone K, Pollack Y. Acetaminophen and Ibuprofen overdosage. Pediatr Rev 2012; 33: 188–9.]